Drugs /

edicotinib

Back to Drugs List

Overview

NCI Definition [1]:
A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS tyrosine kinase inhibitor JNJ-40346527 blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS can not activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells. FMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation, recruitment, and activation as well as the regulation of cell proliferation.

Clinical Trials

View Clinical Trials for edicotinib

Edicotinib has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating edicotinib, 1 is phase 1 (1 open) and 1 is phase 2 (0 open).

Prostate adenocarcinoma is the most common disease being investigated in edicotinib clinical trials [2].

Drug Details

Synonyms [2]:
jnj-40346527, fms inhibitor jnj-40346527, fms inhibitor jnj-40346527
Drug Target(s) [2]:
CSF1R
NCIT ID [1]:
C101519

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.